Similar Response Patterns to 5%Topical Minoxidil Foam in Frontal and Vertex Scalp of Men with Androgenetic Alopecia: A Microarray Analysis.
Mirmirani P1, Consolo M, Oyetakin-White P, Baron E, Leahy P, Karnik P.
Author information
Abstract
BACKGROUND:
There are regional variations in scalp hair miniaturization seen in androgenetic alopecia (Androgenetic Alopecia). Use of topical minoxidil can lead to reversal of miniaturization in the vertex scalp. However, its effects on other scalp regions are less well studied.
METHODS:
A placebo controlled double-blinded prospective pilot study of minoxidil topical foam 5% (MTF) vs placebo was conducted in sixteen healthy men ages 18-49 with Hamilton-Norwood type IV-V thinning. The subjects were asked to apply the treatment (active drug or placebo) to the scalp twice daily for eight weeks. Stereotactic scalp photographs were taken at the baseline and final visits to monitor global hair growth. Scalp biopsies were done at the leading edge of hair loss from the frontal and vertex scalp before and after treatment with MTF and placebo and microarray analysis was done using the Affymetrix GeneChip HG U133 Plus 2.0.
RESULTS:
Global stereotactic photographs showed that MTF induced hair growth in both the frontal and vertex scalp of Androgenetic Alopecia patients. Regional differences in gene expression profiles were observed before treatment. However, MTF treatment induced the expression of hair keratin associated genes and decreased the expression of epidermal differentiation complex (EDC) and inflammatory genes in both scalp regions.
CONCLUSIONS:
These data suggest that MTF is effective in the treatment of both the frontal and vertex scalp of Androgenetic Alopecia patients. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
